A meta-analysis of the therapeutic effects of glucagon-like peptide-1 agonist in heart failure

International Journal of Peptides

Volumn 2012, Issue , 2012, Pages

  Munaf, Mohammed ^a   Pellicori, Pierpaolo ^a   Allgar, Victoria ^a   Wong, Kenneth ^a  

^a CASTLE HILL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPLERENONE; GLUCAGON LIKE PEPTIDE 1; LOOP DIURETIC AGENT; PLACEBO; SPIRONOLACTONE;

ARTICLE; GASTROINTESTINAL SYMPTOM; HEART FAILURE; HEART FUNCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE METABOLISM; HEART RATE; HUMAN; HYPOGLYCEMIA; INSULIN LIKE ACTIVITY; META ANALYSIS (TOPIC); NONHUMAN; PRIORITY JOURNAL; THERAPY EFFECT;

EID: 84879194479     PISSN: 16879767     EISSN: 16879775     Source Type: Journal    
DOI: 10.1155/2012/249827     Document Type: Article

References (39)

1. Hunt S. A., Baker D. W., Chin M. H., ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. A report of the American college of cardiology/American heart association task force on practice guidelines (committee to revise the 1995 guidelines for the evaluation and management of heart failure): developed in collaboration with the international society for heart and lung transplantation; endorsed by the heart failure society of America Circulation 2001 104 24 2996 3007 (Pubitemid 33139116)
2. Bui A. L., Horwich T. B., Fonarow G. C., Epidemiology and risk profile of heart failure Nature Reviews Cardiology 2011 8 1 30 41
3. McMurray J. J. V., Stewart S., The burden of heart failure European Heart Journal 2002 4 supplement D D50 D58
4. Cleland J. G., Torabi A., Khan N. K., Epidemiology and management of heart failure and left ventricular systolic dysfunction in the aftermath of a myocardial infarction Heart 2005 91 supplement 2 ii7ii13, ii31 ii43
5. Hogg K., Swedberg K., McMurray J., Heart failure with preserved left ventricular systolic function: epidemiology, clinical characteristics, and prognosis Journal of the American College of Cardiology 2004 43 3 317 327 (Pubitemid 38167688)
6. Cleland J. G. F., McDonagh T., Rigby A. S., Yassin A., Whittaker T., Dargie H. J., The national heart failure audit for England and Wales 2008-2009 Heart 2011 97 11 876 886
7. Salmasi A. M., Frost P., Dancy M., Left ventricular diastolic function in normotensive subjects 2 months after acute myocardial infarction is related to glucose intolerance American Heart Journal 2005 150 1 168 174 (Pubitemid 41102211)
8. Tsujino T., Kawasaki D., Masuyama T., Left ventricular diastolic dysfunction in diabetic patients: pathophysiology and therapeutic implications American Journal of Cardiovascular Drugs 2006 6 4 219 230 (Pubitemid 44285131)
9. Fujita M., Asanuma H., Kim J., Liao Y., Hirata A., Tsukamoto O., Minamino T., Hori M., Goto M., Node K., Kitakaze M., Impaired glucose tolerance: a possible contributor to left ventricular hypertrophy and diastolic dysfunction International Journal of Cardiology 2007 118 1 76 80 (Pubitemid 46517699)
10. Tamargo J., Lpez-Sendn J., Novel therapeutic targets for the treatment of heart failure Nature Reviews Drug Discovery 2011 10 7 536 555
11. Kieffer T. J., Habener J. F., The glucagon-like peptides Endocrine Reviews 1999 20 6 876 913 (Pubitemid 30647076)
12. Saraceni C., Broderick T. L., Effects of glucagon-like peptide-1 and long-acting analogues on cardiovascular and metabolic function Drugs in R and D 2007 8 3 145 153 (Pubitemid 46707838)
13. Toft-Nielsen M. B., Madsbad S., Holst J. J., Determinants of the effectiveness of glucagon-like peptide-1 in type 2 diabetes Journal of Clinical Endocrinology and Metabolism 2001 86 8 3853 3860 (Pubitemid 32755988)
14. Meier J. J., Weyhe D., Michaely M., Senkal M., Zumtobel V., Nauck M. A., Holst J. J., Schmidt W. E., Gallwitz B., Intravenous glucagon-like peptide 1 normalizes blood glucose after major surgery in patients with type 2 diabetes Critical Care Medicine 2004 32 3 848 851 (Pubitemid 38340086)
15. Monami M., Cremasco F., Lamanna C., Colombi C., Desideri C. M., Iacomelli I., Marchionni N., Mannucci E., Glucagon-like peptide-1 receptor agonists and cardiovascular events: a meta-analysis of randomized clinical trials Experimental Diabetes Research 2011 2011
16. Stanley W. C., Recchia F. A., Lopaschuk G. D., Myocardial substrate metabolism in the normal and failing heart Physiological Reviews 2005 85 3 1093 1129 (Pubitemid 40894649)
17. Essop M. F., Opie L. H., Metabolic therapy for heart failure European Heart Journal 2004 25 20 1765 1768 (Pubitemid 39330225)
18. Taegtmeyer H., Cardiac metabolism as a target for the treatment of heart failure Circulation 2004 110 8 894 896 (Pubitemid 39128613)
19. Grieve D. J., Cassidy R. S., Green B. D., Emerging cardiovascular actions of the incretin hormone glucagon-like peptide-1: potential therapeutic benefits beyond glycaemic control? British Journal of Pharmacology 2009 157 8 1340 1351
20. Nikolaidis L. A., Mankad S., Sokos G. G., Miske G., Shah A., Elahi D., Shannon R. P., Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion Circulation 2004 109 8 962 965 (Pubitemid 38282847)
21. Ban K., Noyan-Ashraf M. H., Hoefer J., Bolz S. S., Drucker D. J., Husain M., Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways Circulation 2008 117 18 2340 2350 (Pubitemid 351653542)
22. Mannucci E., Rotella C. M., Future perspectives on glucagon-like peptide-1, diabetes and cardiovascular risk Nutrition, Metabolism and Cardiovascular Diseases 2008 18 9 639 645
23. Bose A. K., Mocanu M. M., Carr R. D., Brand C. L., Yellon D. M., Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury Diabetes 2005 54 1 146 151 (Pubitemid 40105106)
24. Poornima I., Brown S. B., Bhashyam S., Parikh P., Bolukoglu H., Shannon R. P., Chronic glucagon-like peptide-1 infusion sustains left ventricular systolic function and prolongs survival in the spontaneously hypertensive, heart failure-prone rat Circulation 2008 1 3 153 160
25. Zhao T., Parikh P., Bhashyam S., Bolukoglu H., Poornima I., Shen Y. T., Shannon R. P., Direct effects of glucagon-like peptide-1 on myocardial contractility and glucose uptake in normal and postischemic isolated rat hearts Journal of Pharmacology and Experimental Therapeutics 2006 317 3 1106 1113 (Pubitemid 43764114)
26. Matsubara M., Kanemoto S., Leshnower B. G., Albone E. F., Hinmon R., Plappert T., Gorman J. H., Gorman R. C., Single dose GLP-1-tf ameliorates myocardial ischemia/reperfusion injury Journal of Surgical Research 2011 165 1 38 45
27. Noyan-Ashraf M. H., Abdul Momen M., Ban K., Sadi A. M., Zhou Y. Q., Riazi A. M., Baggio L. L., Henkelman R. M., Husain M., Drucker D. J., GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice Diabetes 2009 58 4 975 983
28. Nikolaidis L. A., Elahi D., Hentosz T., Doverspike A., Huerbin R., Zourelias L., Stolarski C., Shen Y. T., Shannon R. P., Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy Circulation 2004 110 8 955 961 (Pubitemid 39128621)
29. Nikolaidis L. A., Elahi D., Shen Y. T., Shannon R. P., Active metabolite of GLP-1 mediates myocardial glucose uptake and improves left ventricular performance in conscious dogs with dilated cardiomyopathy American Journal of Physiology-Heart and Circulatory Physiology 2005 289 6 H2401 H2408
30. Thrainsdottir I., Malmberg K., Olsson A., Gutniak M., Rydén L., Initial experience with GLP-1 treatment on metabolic control and myocardial function in patients with type 2 diabetes mellitus and heart failure Diabetes Vascular Disease Research 2004 1 1 40 43
31. Sokos G. G., Nikolaidis L. A., Mankad S., Elahi D., Shannon R. P., Glucagon-Like Peptide-1 Infusion Improves Left Ventricular Ejection Fraction and Functional Status in Patients With Chronic Heart Failure Journal of Cardiac Failure 2006 12 9 694 699 (Pubitemid 44881367)
32. Halbirk M., Nrrelund H., Mller N., Holst J. J., Schmitz O., Nielsen R., Nielsen-Kudsk J. E., Nielsen S. S., Nielsen T. T., Eiskjr H., Btker H. E., Wiggers H., Cardiovascular and metabolic effects of 48-h glucagon-like peptide-1 infusion in compensated chronic patients with heart failure American Journal of Physiology-Heart and Circulatory Physiology 2010 298 3 H1096 H1102
33. Mendis B., Simpson E., Macdonald I., Mansell P., Investigation of the haemodynamic effects of exenatide in healthy male subjects. British Journal of Clinical Pharmacology. In press
34. Cleland J. G., Pennell D. J., Ray S. G., Carvedilol hibernating reversible ischaemia trial: marker of success investigators. Myocardial viability as a determinant of the ejection fraction response to carvedilol in patients with heart failure (CHRISTMAS trial): randomised controlled trial The Lancet 2003 362 9377 14 21 (Pubitemid 36840896)
35. Coletta A. P., Cleland J. G. F., Cullington D., Clark A. L., Clinical trials update from heart rhythm 2008 and heart failure 2008: ATHENA, URGENT, INH study, HEART and CK-1827452 European Journal of Heart Failure 2008 10 9 917 920
36. Velazquez E. J., Lee K. L., Deja M. A., Jain A., Sopko G., Marchenko A., Ali I. S., Pohost G., Gradinac S., Abraham W. T., Yii M., Prabhakaran D., Szwed H., Ferrazzi P., Petrie M. C., O'Connor C. M., Panchavinnin P., She L., Bonow R. O., Rankin G. R., Jones R. H., Rouleau J. L., STICH Investigators, Coronary-artery bypass surgery in patients with left ventricular dysfunction The New England Journal of Medicine 2011 364 17 1607 1616
37. Fox K., Ford I., Steg P.G., Tendera M., Robertson M., Ferrari R., On behalf of the BEAUTIFUL investigators/Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial The Lancet 2008 372 9641 817 821
38. Galderisi M., Lomoriello V. S., Santoro A., Esposito R., Olibet M., Raia R., Dario Di Minno M. N., Guerra G., Mele D., Lombardi G., Differences of myocardial systolic deformation and correlates of diastolic function in competitive rowers and young hypertensives: a speckle-tracking echocardiography study Journal of the American Society of Echocardiography 2010 23 11 1190 1198
39. Nahum J., Bensaid A., Dussault C., Macron L., Clémence D., Bouhemad B., Monin J. L., Rande J. L. D., Gueret P., Lim P., Impact of longitudinal myocardial deformation on the prognosis of chronic heart failure patients Circulation Cardiovascular Imaging 2010 3 3 249 256